GlobeNewswire: TG Therapeutics, Inc. Contains the last 10 of 490 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T02:36:10ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/08/2843057/0/en/TG-Therapeutics-Announces-Schedule-of-Data-Presentations-for-BRIUMVI-ublituximab-in-Multiple-Sclerosis-at-the-American-Academy-of-Neurology-2024-Annual-Meeting.html?f=22&fvtc=4&fvtv=6828TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting2024-03-08T12:30:00Z<![CDATA[NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology 2024 annual meeting, being held April 13 - 18, 2024, in Dever, Colorado. Abstracts are now available online and can be accessed on the AAN meeting website at https://www.aan.com/msa/Public/Events/Index/49. Details of the upcoming presentations are outlined below.]]>https://www.globenewswire.com/news-release/2024/03/01/2838758/0/en/TG-Therapeutics-Announces-Presentation-of-Data-for-BRIUMVI-in-Multiple-Sclerosis-at-the-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis-Annual-Forum.html?f=22&fvtc=4&fvtv=6828TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum2024-03-01T12:30:00Z<![CDATA[NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held in West Palm Beach, Florida. Links to each presentation are included below.]]>https://www.globenewswire.com/news-release/2024/02/28/2836785/0/en/TG-Therapeutics-Provides-Business-Update-and-Reports-Fourth-Quarter-and-Year-End-2023-Financial-Results.html?f=22&fvtc=4&fvtv=6828TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results2024-02-28T12:00:00Z<![CDATA[Fourth quarter and full year 2023 BRIUMVI U.S. net revenue of approximately $40 million and $89 million, respectively]]>https://www.globenewswire.com/news-release/2024/02/27/2835897/0/en/TG-Therapeutics-Announces-Issuance-of-Additional-Patents-for-BRIUMVI-ublituximab-xiiy.html?f=22&fvtc=4&fvtv=6828TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)2024-02-27T12:30:00Z<![CDATA[Newly issued patents extend exclusivity of ublituximab through 2042 Newly issued patents extend exclusivity of ublituximab through 2042]]>https://www.globenewswire.com/news-release/2024/02/26/2835010/0/en/TG-Therapeutics-Announces-European-Launch-of-BRIUMVI-ublituximab-xiiy.html?f=22&fvtc=4&fvtv=6828TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)2024-02-26T12:00:00Z<![CDATA[Ex-US partner, Neuraxpharm, launches BRIUMVI in Germany, the first European country Ex-US partner, Neuraxpharm, launches BRIUMVI in Germany, the first European country]]>https://www.globenewswire.com/news-release/2024/02/23/2834408/0/en/TG-Therapeutics-to-Host-Conference-Call-on-Fourth-Quarter-and-Year-End-2023-Financial-Results-and-Business-Update.html?f=22&fvtc=4&fvtv=6828TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update2024-02-23T12:30:00Z<![CDATA[Conference call to be held Wednesday, February 28, 2024, at 8:30 AM ET Conference call to be held Wednesday, February 28, 2024, at 8:30 AM ET]]>https://www.globenewswire.com/news-release/2024/02/20/2831720/0/en/TG-Therapeutics-Announces-Schedule-of-Data-Presentations-for-BRIUMVI-ublituximab-in-Multiple-Sclerosis-at-the-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis-An.html?f=22&fvtc=4&fvtv=6828TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum2024-02-20T12:30:00Z<![CDATA[NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 29 – March 2, 2024, in West Palm Beach, Florida. Abstracts are now available online and can be accessed on the ACTRIMS meeting website at www.forum.actrims.org. Details of the upcoming presentations are outlined below.]]>https://www.globenewswire.com/news-release/2024/01/10/2806976/0/en/TG-Therapeutics-Provides-Preliminary-Fourth-Quarter-and-Full-Year-2023-Net-Revenue-and-2024-Anticipated-Milestones.html?f=22&fvtc=4&fvtv=6828TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones2024-01-10T12:00:00Z<![CDATA[Preliminary U.S. BRIUMVI fourth quarter and full year 2023 net product revenue of approximately $40 million and $89 million, respectively]]>https://www.globenewswire.com/news-release/2024/01/09/2806141/0/en/TG-Therapeutics-Announces-Global-License-Agreement-with-Precision-BioSciences-for-the-Development-and-Commercialization-of-Precision-s-Allogeneic-CD19-CAR-T-Cell-Therapy-Program-fo.html?f=22&fvtc=4&fvtv=6828TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases2024-01-09T12:00:00Z<![CDATA[US IND filing targeted for mid-2024 US IND filing targeted for mid-2024]]>https://www.globenewswire.com/news-release/2024/01/05/2804584/0/en/TG-Therapeutics-to-Participate-in-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=6828TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference2024-01-05T12:30:00Z<![CDATA[Presentation scheduled for Tuesday, January 9, 2024, at 4:30 PM PT Presentation scheduled for Tuesday, January 9, 2024, at 4:30 PM PT]]>